Drug Trial Radar · NCT05162118
Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer
Last checked: Nov 20, 2026Latest source record: Mar 9, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
51
Planned (sponsor's estimate)
Start
Mar 8, 2022
Primary completion
Mar 22, 2025
Study completion Dec 22, 2025
Sponsor
- Lead sponsor
- Zhejiang UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
VG161 is a recombinant human-IL12/15/PDL1B oncolytic HSV-1 Injectable. This is a multicenter, open, single-arm design clinical trial coducted in HSV-seropositive subjects with advanced pancreatic cancer to determine the safety, tolerability and preliminary efficacy of VG161 combined with PD-1 inhibitor (Nivolumab Injection).
Conditions
- Advanced Pancreatic Cancer
Interventions
Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)) in combination with NivolumabDrug
Intratumoral injection of VG161 on day 1 only or day 1 through 3, in combination of Nivolumab intravenous injection only, Once every 2 weeks, 3 mg/kg each time.
Primary outcomes
What the sponsor says the trial is designed to measure.
- MTDTime frame: 1 month
- Occurrence and numbers of DLT (phase 1)Time frame: 1 month
- Occurence and frequence of AE and SAE (phase 1)Time frame: 24 month
- DCR (phase 2)Time frame: 24 month
- RP2D (phase 1)Time frame: 1 month
Locations
1 site in 1 country. Site status is shown where the registry gives one.
the First Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.